Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis
Gemcitabine (GEM) is an approved treatment for unresectable pancreatic cancer; however, its role in treating resected pancreatic cancer is less clear. The aim of this study was to investigate the evidence of the role of adjuvant GEM therapy on survival in resected pancreatic cancer. Four phase III r...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical oncology 2015-06, Vol.38 (3), p.322-325 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 325 |
|---|---|
| container_issue | 3 |
| container_start_page | 322 |
| container_title | American journal of clinical oncology |
| container_volume | 38 |
| creator | Yu, Zhong Zhong, Wa Tan, Zhi-Ming Wang, Ling-Yun Yuan, Yu-Hong |
| description | Gemcitabine (GEM) is an approved treatment for unresectable pancreatic cancer; however, its role in treating resected pancreatic cancer is less clear. The aim of this study was to investigate the evidence of the role of adjuvant GEM therapy on survival in resected pancreatic cancer. Four phase III randomized trials of adjuvant GEM in patients with resected pancreatic cancer were identified and the hazard ratio (HR) for overall survival were used in this meta-analysis; 2 studies compared GEM treatment with best supportive care and 2 studies with 5-fluorouracil/folinic acid therapy. The pooled data (n=2017 patients) indicated that the overall survival data were homogenous among the studies (Q=4.371; I=31.37%; P=0. 224). The combined HR significantly favors GEM over the other treatments. The overall HR was 0.88 (range, 0. 720 to 0.940; P=0.014). The results indicate that GEM prolongs overall survival compared with other treatments after the resection of pancreatic cancer. |
| doi_str_mv | 10.1097/COC.0b013e3182a46782 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1683076783</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1683076783</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-904a798ac77f5e2a864a87e200692d01f006005ab88c917b7ef2719dc46072693</originalsourceid><addsrcrecordid>eNpdkEtLw0AUhQdRbK3-A5FZukmdVzIZdyVoFSoVqeAu3ExuMCWPOpMI_feOVF24umdxzrmHj5BLzuacGX2TrbM5KxiXKHkqQCU6FUdkymOpIxXLt2MyZULrSGopJuTM-y1jLE6YPiUTIY1UXKopWS2xtfUARd0hXZTb8RO6gW7e0cFuT6ve0Rf0aAcs6TN01iEMtaVZkOhu6YI-4QARdNDsfe3PyUkFjceLnzsjr_d3m-whWq2Xj9liFVkRJ0NkmAJtUrBaVzEKSBMFqUbBWGJEyXgVRJgKRZpaw3WhsRKam9KqsF4kRs7I9aF35_qPEf2Qt7W32DTQYT_6nCepZDoAkcGqDlbreu8dVvnO1S24fc5Z_s0xDxzz_xxD7Ornw1i0WP6FfsHJLxA2bRo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1683076783</pqid></control><display><type>article</type><title>Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Yu, Zhong ; Zhong, Wa ; Tan, Zhi-Ming ; Wang, Ling-Yun ; Yuan, Yu-Hong</creator><creatorcontrib>Yu, Zhong ; Zhong, Wa ; Tan, Zhi-Ming ; Wang, Ling-Yun ; Yuan, Yu-Hong</creatorcontrib><description>Gemcitabine (GEM) is an approved treatment for unresectable pancreatic cancer; however, its role in treating resected pancreatic cancer is less clear. The aim of this study was to investigate the evidence of the role of adjuvant GEM therapy on survival in resected pancreatic cancer. Four phase III randomized trials of adjuvant GEM in patients with resected pancreatic cancer were identified and the hazard ratio (HR) for overall survival were used in this meta-analysis; 2 studies compared GEM treatment with best supportive care and 2 studies with 5-fluorouracil/folinic acid therapy. The pooled data (n=2017 patients) indicated that the overall survival data were homogenous among the studies (Q=4.371; I=31.37%; P=0. 224). The combined HR significantly favors GEM over the other treatments. The overall HR was 0.88 (range, 0. 720 to 0.940; P=0.014). The results indicate that GEM prolongs overall survival compared with other treatments after the resection of pancreatic cancer.</description><identifier>ISSN: 0277-3732</identifier><identifier>EISSN: 1537-453X</identifier><identifier>DOI: 10.1097/COC.0b013e3182a46782</identifier><identifier>PMID: 23934134</identifier><language>eng</language><publisher>United States</publisher><subject>Antimetabolites, Antineoplastic - therapeutic use ; Chemotherapy, Adjuvant ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Humans ; Pancreatectomy ; Pancreatic Neoplasms - therapy ; Survival Rate</subject><ispartof>American journal of clinical oncology, 2015-06, Vol.38 (3), p.322-325</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-904a798ac77f5e2a864a87e200692d01f006005ab88c917b7ef2719dc46072693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23934134$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yu, Zhong</creatorcontrib><creatorcontrib>Zhong, Wa</creatorcontrib><creatorcontrib>Tan, Zhi-Ming</creatorcontrib><creatorcontrib>Wang, Ling-Yun</creatorcontrib><creatorcontrib>Yuan, Yu-Hong</creatorcontrib><title>Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis</title><title>American journal of clinical oncology</title><addtitle>Am J Clin Oncol</addtitle><description>Gemcitabine (GEM) is an approved treatment for unresectable pancreatic cancer; however, its role in treating resected pancreatic cancer is less clear. The aim of this study was to investigate the evidence of the role of adjuvant GEM therapy on survival in resected pancreatic cancer. Four phase III randomized trials of adjuvant GEM in patients with resected pancreatic cancer were identified and the hazard ratio (HR) for overall survival were used in this meta-analysis; 2 studies compared GEM treatment with best supportive care and 2 studies with 5-fluorouracil/folinic acid therapy. The pooled data (n=2017 patients) indicated that the overall survival data were homogenous among the studies (Q=4.371; I=31.37%; P=0. 224). The combined HR significantly favors GEM over the other treatments. The overall HR was 0.88 (range, 0. 720 to 0.940; P=0.014). The results indicate that GEM prolongs overall survival compared with other treatments after the resection of pancreatic cancer.</description><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Chemotherapy, Adjuvant</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Humans</subject><subject>Pancreatectomy</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>Survival Rate</subject><issn>0277-3732</issn><issn>1537-453X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkEtLw0AUhQdRbK3-A5FZukmdVzIZdyVoFSoVqeAu3ExuMCWPOpMI_feOVF24umdxzrmHj5BLzuacGX2TrbM5KxiXKHkqQCU6FUdkymOpIxXLt2MyZULrSGopJuTM-y1jLE6YPiUTIY1UXKopWS2xtfUARd0hXZTb8RO6gW7e0cFuT6ve0Rf0aAcs6TN01iEMtaVZkOhu6YI-4QARdNDsfe3PyUkFjceLnzsjr_d3m-whWq2Xj9liFVkRJ0NkmAJtUrBaVzEKSBMFqUbBWGJEyXgVRJgKRZpaw3WhsRKam9KqsF4kRs7I9aF35_qPEf2Qt7W32DTQYT_6nCepZDoAkcGqDlbreu8dVvnO1S24fc5Z_s0xDxzz_xxD7Ornw1i0WP6FfsHJLxA2bRo</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Yu, Zhong</creator><creator>Zhong, Wa</creator><creator>Tan, Zhi-Ming</creator><creator>Wang, Ling-Yun</creator><creator>Yuan, Yu-Hong</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150601</creationdate><title>Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis</title><author>Yu, Zhong ; Zhong, Wa ; Tan, Zhi-Ming ; Wang, Ling-Yun ; Yuan, Yu-Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-904a798ac77f5e2a864a87e200692d01f006005ab88c917b7ef2719dc46072693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Chemotherapy, Adjuvant</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Humans</topic><topic>Pancreatectomy</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yu, Zhong</creatorcontrib><creatorcontrib>Zhong, Wa</creatorcontrib><creatorcontrib>Tan, Zhi-Ming</creatorcontrib><creatorcontrib>Wang, Ling-Yun</creatorcontrib><creatorcontrib>Yuan, Yu-Hong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yu, Zhong</au><au>Zhong, Wa</au><au>Tan, Zhi-Ming</au><au>Wang, Ling-Yun</au><au>Yuan, Yu-Hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis</atitle><jtitle>American journal of clinical oncology</jtitle><addtitle>Am J Clin Oncol</addtitle><date>2015-06-01</date><risdate>2015</risdate><volume>38</volume><issue>3</issue><spage>322</spage><epage>325</epage><pages>322-325</pages><issn>0277-3732</issn><eissn>1537-453X</eissn><abstract>Gemcitabine (GEM) is an approved treatment for unresectable pancreatic cancer; however, its role in treating resected pancreatic cancer is less clear. The aim of this study was to investigate the evidence of the role of adjuvant GEM therapy on survival in resected pancreatic cancer. Four phase III randomized trials of adjuvant GEM in patients with resected pancreatic cancer were identified and the hazard ratio (HR) for overall survival were used in this meta-analysis; 2 studies compared GEM treatment with best supportive care and 2 studies with 5-fluorouracil/folinic acid therapy. The pooled data (n=2017 patients) indicated that the overall survival data were homogenous among the studies (Q=4.371; I=31.37%; P=0. 224). The combined HR significantly favors GEM over the other treatments. The overall HR was 0.88 (range, 0. 720 to 0.940; P=0.014). The results indicate that GEM prolongs overall survival compared with other treatments after the resection of pancreatic cancer.</abstract><cop>United States</cop><pmid>23934134</pmid><doi>10.1097/COC.0b013e3182a46782</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-3732 |
| ispartof | American journal of clinical oncology, 2015-06, Vol.38 (3), p.322-325 |
| issn | 0277-3732 1537-453X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1683076783 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Antimetabolites, Antineoplastic - therapeutic use Chemotherapy, Adjuvant Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Humans Pancreatectomy Pancreatic Neoplasms - therapy Survival Rate |
| title | Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T00%3A07%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gemcitabine%20Adjuvant%20Therapy%20for%20Resected%20Pancreatic%20Cancer:%20A%20Meta-analysis&rft.jtitle=American%20journal%20of%20clinical%20oncology&rft.au=Yu,%20Zhong&rft.date=2015-06-01&rft.volume=38&rft.issue=3&rft.spage=322&rft.epage=325&rft.pages=322-325&rft.issn=0277-3732&rft.eissn=1537-453X&rft_id=info:doi/10.1097/COC.0b013e3182a46782&rft_dat=%3Cproquest_cross%3E1683076783%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1683076783&rft_id=info:pmid/23934134&rfr_iscdi=true |